다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
HUTCHMED China Limited (HCM)
HUTCHMED China Limited (HCM) 뉴스

HCM

HUTCHMED China (HCM)

HUTCHMED China Limited

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/08	17:30	GlobeNewswire Inc.	HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee	NASDAQ:HCM	HUTCHMED China Limited
2024/04/26	21:30	GlobeNewswire Inc.	HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda	NASDAQ:HCM	HUTCHMED China Limited
2024/04/05	17:30	GlobeNewswire Inc.	HUTCHMED Highlights Data to be Presented at AACR Congress 2024	NASDAQ:HCM	HUTCHMED China Limited
2024/04/02	13:30	GlobeNewswire Inc.	HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2024/03/28	09:00	GlobeNewswire Inc.	HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	NASDAQ:HCM	HUTCHMED China Limited
2024/03/22	09:00	GlobeNewswire Inc.	HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	NASDAQ:HCM	HUTCHMED China Limited
2024/03/05	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20:47	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20:40	Edgar (US Regulatory)	Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/28	20:30	GlobeNewswire Inc.	HUTCHMED Reports 2023 Full Year Results and Provides Business Updates	NASDAQ:HCM	HUTCHMED China Limited
2024/02/07	20:43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/07	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session	NASDAQ:HCM	HUTCHMED China Limited
2024/02/02	20:15	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/02	17:30	GlobeNewswire Inc.	HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership	NASDAQ:HCM	HUTCHMED China Limited
2024/02/01	20:06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/02/01	17:30	GlobeNewswire Inc.	HUTCHMED to Announce 2023 Final Results	NASDAQ:HCM	HUTCHMED China Limited
2024/01/30	20:17	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/01/30	13:53	GlobeNewswire Inc.	HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer	NASDAQ:HCM	HUTCHMED China Limited
2024/01/11	20:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2024/01/11	09:00	GlobeNewswire Inc.	HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status	NASDAQ:HCM	HUTCHMED China Limited
2023/12/29	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/21	20:14	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	13:30	GlobeNewswire Inc.	HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms	NASDAQ:HCM	HUTCHMED China Limited
2023/12/13	09:00	GlobeNewswire Inc.	HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China	NASDAQ:HCM	HUTCHMED China Limited
2023/12/07	20:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/01	20:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/12/01	09:00	GlobeNewswire Inc.	HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses	NASDAQ:HCM	HUTCHMED China Limited
2023/11/30	20:09	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:HCM	HUTCHMED China Limited
2023/11/10	22:35	GlobeNewswire Inc.	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing	NASDAQ:HCM	HUTCHMED China Limited

검색 관련기사 보기:NASDAQ:HCM

1 2 3 4 5 6 7 8 9 10 다음 >>

US Dollar vs Euro

US Dollar vs Sterling

American Express

Gold vs US Dollar

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관